Editorial: Worsening heart failure: challenges, treatments, future perspectives
Abstract
Heart failure (HF) remains a major global health challenge, with rising prevalence and significant implications for morbidity and mortality [1]. The clinical course of HF is characterized by the decline in clinical status of the patients till the occurrence of the final outcome [2]. Each recurrence reduces the fullrecovery of the patient and worsens his/her functional status.Escalating signs and symptoms of HF in patients with chronic HF despite previously stable therapy define Worsening Heart Failure (WHF) status which recently emerges as the most intriguing clinical condition to be firmly addressed for preventing the worst outcome of HF [3]. This implies the use of e.v. diuretics and the need for possible hospitalization and/or urgent outpatient evaluation.The management of WHF is challenging as no definite therapy is able to counteract the outcome of patients who suffered for it. Despite the clinical benefit from the use of Empagliflozin in patients who are hospitalized for acute heart failure, the EMPagliflozin 10 mg compared with placebo, initiated in patients hospitalized for acUte heart faiLure who have been StabilisEd (EMPULSE) study did not demonstrate a definitely reduction in hospitalization for HF, cardiovascular death, and total HF hospitalizations [4].Indeed, the use of Vericiguat -an oral soluble guanylate cyclase stimulator -in the setting of WHF effectively reduced the composite outcome of death from cardiovascular causes or first hospitalization for heart…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.